Aspiring to develop a positron emission tomography (PET) imaging agent for the GluN2B subunits of the <i>N</i>-methyl-d-aspartate receptor (NMDAR), a key therapeutic target for drug development toward several neurological disorders, we synthesized a series of 2,3,4,5-tetrahydro-1<i>H</i>-3-benzazepine and 6,7,8,9-tetrahydro-5<i>H</i>-benzo[7]annulen-7-amine analogues.
Clinical and preclinical research with modulators at the <i>N</i>-methyl-d-aspartate (NMDA) receptor GluN2B N-terminal domain (NTD) aims for the treatment of various neurologic diseases.
The NMDA receptor containing GluN2B subunits represents a promising target for the development of drugs for the treatment of various neurological disorders including neurodegenerative diseases.
Antagonists addressing selectively NMDA receptors containing the GluN2B subunit are of particular interest for the treatment of various neurological disorders including neurodegenerative diseases.
Antagonists that selectively target GluN2B-subunit-containing N-methyl-d-aspartate (NMDA) receptors are of major interest for the treatment of various neurological disorders.